Background: If new advances in stroke management are to be put into practice, crucial information about their costs needs to be considered in relation to clinically pertinent variables (e.g. handicap level and stroke subtypes). Details of costs throughout the entire period of stroke care are essential in the political decision-making process, in order to avoid other budget-balancing approaches, which are not always satisfactory. Our aim was to perform an in-depth evaluation of the direct medical cost of stroke care in a large cohort. Methods: We included 435 consecutive patients with brain infarction in 12 primary-care and referral neurology departments. Information on acute care was prospectively collected. Information on postacute care was collected by research nurses’ visits to the patient’s or a relative’s home 18–40 months after the stroke onset. We thus collected detailed information on handicap levels, stroke subtypes, acute hospitalization costs, rehabilitation, nursing care and ambulatory costs. This enabled us to calculate costs over an 18-month period after the initial acute hospital discharge. Results: By the 12th month after discharge, the costs amounted to 17,799 euros (16,440–19,158) per patient; the initial hospitalization accounted for 42% of this cost, rehabilitation for 29% and ambulatory care for 8%. These costs were mostly concentrated within the first 3- to 6-month period. After 46 months without recurrence, the cost of ambulatory care outweighed the cost of the first 6 months. Handicap levels explained 43% of the variance of costs (p < 0.0001) and, according to the Rankin scale divided into 3 classes (0–2, 3 and 4–5), cumulative costs over time differed considerably. Stroke subtypes were not discriminating variables except for lacunar strokes, which were significantly less costly than the other groups. Conclusions: By providing a fairly comprehensive figure for the details of direct costs of stroke care over time, our study gives some clues about the economic burden of stroke care which is mostly driven by a high handicap level. This suggests that any early intervention aimed at reducing the handicap level will probably dramatically reduce this burden.

Keywords:
Brain infarct, Cost, Handicap levels, Stroke subtypes
1.
Murray CJL, Lopez AD: Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet 1997;349:1498–1504.
2.
Bonita R: Epidemiology of stroke. Lancet 1992;339:342.
3.
Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P: Antithrombotic and thrombolytic therapy for ischemic stroke. Chest 2001;119:300S-320S.
4.
Stroke Unit Trialists’ Collaboration: A systematic review of randomized trials of organised inpatient (stroke unit) care after stroke. Br Med J 1997;314:1151–1159.
5.
Terént A, Marké L-A, Asplund K, Norrving B, Jonsson E, Wester PO: Costs of stroke in Sweden: A national perspective. Stroke 1994;25:2363–2369.
6.
Taylor TN: The medical economics of stroke. Drugs 1997;5(suppl 3):51–58.
7.
Evers SM, Engel GL, Ament AJ: Cost of stroke in the Netherlands from a societal perspective. Stroke 1997;28:1375–1381.
8.
Smurawska LT, Alexandrov AV, Bladin CF, Norris JW: Cost of acute stroke care in Toronto, Canada. Stroke 1994;25:1628–1631.
9.
Isard PA, Forbes JF: The cost of stroke to the National Health Service in Scotland. Cerebrovasc Dis 1992;2:47–50.
10.
Gorelick PB, et al: Prevention of a first stroke: A review of guidelines and a multidisciplinary consensus statement from the National Stroke Association. JAMA 1999;281:1112–1120.
11.
Kaste M, Skyhoj Olsen T, Orgogozo JM, Bogousslavsky J, Hacke W, for the European Stroke Initiative (EUSI) Executive Committee: Organization of stroke care: Education, stroke units and rehabilitation. Cerebrovasc Dis 2000;10(suppl 3):1–11.
12.
Spieler J-F, Lanoë J-L, Amarenco P: Socio-economic aspects of postacute care for patients with brain infarction in France. Cerebrovasc Dis 2002;13:132–141.
13.
Elbaz A, Poirier O, Canaple S, Chédru F, Cambien F, Amarenco P, on behalf of the GÉNIC investigators: The association between the Val34Leu polymorphism in the factor XIII gene and brain infarction. Blood 2000;95:586–591.
14.
Spieler J-F, de Pouvourville G, Amarenco P: Comparison between the cost of a recurrent stroke and a first-ever stroke over an 18-month period. Eur J Neurol, in press.
15.
Hartmann A, Rundek T, Mast H, Paik MC, Boden-Albala B, Mohr JP, Sacco RL: Mortality and causes of death after first ischemic stroke: The Northern Manhattan Stroke Study. Neurology 2001;57:2000–2005.
© 2004 S. Karger AG, Basel
2003
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.